AR AR-V7

CI-VAR-00000175Explore in graph →CIViC 362

Curated evidence

Evidence by cancer (16 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–16 of 16 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Prostate Neoplasm15
AR AR-V7	(prognostic)	Prognostic	B	Supports Poor Outcome	3	submitted	EID12376 Analysis was performed on 224 advanced prostate cancer (PCA) patient samples which had clinical outcome information. Elevated PSA levels in patients after radical prostatectomy are associated with me… (full text at CIViC) PMID 19244107 · Guo et al., 2009 · Open in CIViC	civic
AR AR-V7	(oncogenic)	Oncogenic	D	Supports Oncogenicity	4	accepted	EID12258 Using a panel of three androgen-insensitive prostate cancer cell lines (C-81, CWR-R1 and 22Rv1), a novel AR protein isoform was identified. This protein was found to be encoded by three novel alternat… (full text at CIViC) PMID 19244107 · Guo et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Salivary Gland Neoplasm1
AR AR-V7	Abiraterone Acetate	Predictive	C	Supports Resistance	2	submitted	EID6954 Case Report of a Patient with metastatic salivary gland cancer with androgen receptor overexpression under treatment with abiraterone. The patient experienced stable disease for 6 months. Analysis of … (full text at CIViC) PMID 29897400 · Cappelletti et al., 2018 · Open in CIViC	civic